Hi y’all,
I thought this article from this month’s Nephrology News & Issues, by some folks whose names may be familiar to you, was a great summary of recommendations to protect home therapies (especially longer and/or more frequent home HD) when the MIPPA bundle comes out. Good background, because rumor has it that the notice of proposed rulemaking–the start of the public comment period–will be at the end of this month.
NN&I Editor’s note: The following position statement was prepared by the Home Hemodialysis Workgroup, an informal coalition of patients, providers, physicians, technology suppliers, and others convened to discuss and summarize priorities on issues impacting access to home dialysis modalities, and, in particular, more frequent home hemodialysis. The group has organized to proactively discuss and create a voice “so that this important patient option may be supported, and not inadvertently discouraged, in this time of major legislative and payment system change,” the group said in submitting the position paper to NN&I.
Background
Home dialysis enables individuals with failed kidneys to receive ongoing life-sustaining dialysis in settings and at times minimally disruptive to their personal, family, and work lives, and is an important option for rural beneficiaries who otherwise must travel significant distances for care in a dialysis center three times a week. Home dialysis includes various modalities of peritoneal dialysis (PD) and home hemodialysis (HHD). PD is a well-recognized treatment currently used by some 7% of U.S. patients, although much more widely used in Canada, Australia, New Zealand and elsewhere.
Research has shown that frequent (4 to 6 times a week) and/or longer (6 to 8 hours per session) HHD are more effective than in-center hemodialysis in improving patients’ health, well-being, and energy; help to significantly reduce costly cardiovascular complications and hospitalizations; and allow maintained employment and rehabilitation.1,2 Even so, only 1% of dialysis patients utilize home HD, despite clinician preference for this modality3 and its appropriateness for at least an estimated 12%-16% percent of dialysis patients.4 Limited utilization has resulted in large part from Medicare payment policies that have discouraged HHD and economically favored delivery of in-center hemodialysis.
Issue
The Medicare Improvements for Patients and Providers Act (MIPPA) calls for significant dialysis payment changes. MIPPA directs CMS to implement, beginning in 2011, a bundled payment for routine dialysis service that incorporates items and services in the current composite payment rate and also certain drugs and laboratory tests that heretofore are separately billable.
Current law and documented proceedings clearly express Congress’ support for policies to ensure beneficiary access to home dialysis, including more frequent HHD and PD.5 Congress wants payment policy to encourage home dialysis so that patient preferences and physician clinical judgment, not economics, are the primary determinants in choosing the best setting for care.
CMS anticipates that the bundling process will inherently encourage home dialysis;6 however the extremely low number of HHD patients today and the declining numbers of PD patients suggest economic disincentives to home therapy will exacerbate with bundling cost pressures. More frequent HHD costs for supplies and equipment are higher than for thrice-weekly in-center, and staffing costs for all forms of home dialysis are significant due to intensive up-front patient self-training and new Conditions for Coverage requirements. Unfortunately, Medicare sources do not fully capture current cost data necessary to ensure that by 2011 the bundle will appropriately reflect adequate payment for home dialysis services, especially more frequent HHD services.
Recommendations
A single, bundled payment for all dialysis modalities paid on a weekly or monthly basis (which assumes a conventional three times a week treatment schedule and ignores training costs) will exacerbate current disincentives toward all forms of home dialysis. Fewer, rather than more, beneficiaries will have access to home dialysis. To avoid this adverse outcome, CMS is encouraged to:
[b]1. Retain the “treatment” as the unit of payment for home hemodialysis under the expanded bundle, and maintain existing provisions for Medicare payment for all prescribed, medically justified treatments.7
-
Maintain home training payment separate from the routine dialysis bundle and update the payment level based on resource use associated with delivery of training services.*
-
Modify CMS claims coding and cost report instructions so that CMS can better track home dialysis utilization and costs. Over time CMS can then consider payment modifications to achieve Congress’ intent with respect to beneficiaries’ access to home therapy. [/b]
References
-
The renaissance of home hemodialysis: Lessons from the world over. Christopher Blagg, Todd ING, Peter Kerr, and Claudio Ronco , eds. Hemodialysis International, 2008 Jul; 12 Suppl1: S1-SS65
-
Contemporary trends in home dialysis, Christopher T. Chan, MD, Charmaine E. Lok, MD, eds. Advances in Chronic Kidney Disease, 2009 May; 16(3): 156-220
-
Ledebo I. The best dialysis therapy? Results from an international survey among nephrology professionals. Nephrol Dial Transplant, 2008
-
Mendelssohn DC et al. What do American nephrologists think about dialysis modality selection? Am J Kidney Dis, 37(1), 2001
-
Sec. 1881 ©(6) of the Social Security Act; Chairman Stark comments in Congressional Record-House, June 24, 2008, p. H5908
-
GAO-090-537 CMS should monitor effect of bundled payment on home dialysis utilization rates, May 2009, p.15
-
Medicare Benefit Policy Manual, Ch. 11, ß 30.1(A); Medicare Provider Reimbursement Manual, Part 1, Chapter 27 ß 2709
- Provider payments for self-dialysis training have not been updated since 1983, and do not reflect current processes or resource requirements.
This position paper was prepared/approved by:
Christopher R. Blagg MD, FRCP
Professor Emeritus of Medicine, University of Washington
Executive Director Emeritus,
Northwest Kidney Centers, Seattle
Robert Blaser
Director of Public Policy
Renal Physicians Association
Mark Burke
Chief Executive Officer
Satellite Healthcare
Michelle Carver, RN, BSN, CNN
Director of Clinical Services -
Home Programs
Renal Advantage Inc.
Dolph Chianchiano
Senior Vice President, Health Policy
and Research
National Kidney Foundation
Larry Emerson, FACHE
Chief Executive Officer
Dialysis Center of Lincoln
Wayne A. Evancoe
CEO/Renal Administrator
Hortense and Louis Rubin Dialysis
Center, Inc.
Lori Hartwell
President/Founder
Renal Support Network
Joyce Jackson
President & CEO
Northwest Kidney Centers
Stan Langhofer
Chief Executive/Administrator
Kansas Dialysis Services
Kathe LeBeau
weKAN Program Manager
Renal Support Network
Home Hemodialyzor
Robert Lockridge, Jr., MD
Lynchburg Nephrology
Bill Peckham
Home Hemodialyzor and Founder, “Dialysis from the Sharp End of
the Needle”
Linda Upchurch
Director of Public Policy
NxStage Medical